Alfredo José
Lucendo Villarín
Publicaciones en las que colabora con Alfredo José Lucendo Villarín (33)
2024
-
A Novel, Noninvasive Method to Diagnose Active Eosinophilic Esophagitis, Combining Clinical Data and Oral Cavity RNA Levels
Clinical Gastroenterology and Hepatology
-
Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry
Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264
-
Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes
Journal of Crohn's and Colitis, Vol. 18, Núm. 3, pp. 349-359
-
Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg)
Helicobacter, Vol. 29, Núm. 4
-
Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management
United European Gastroenterology Journal, Vol. 12, Núm. 1, pp. 122-138
-
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5
2023
-
Author Correction: Comparison of the management of Helicobacter pylori infection between the older and younger European populations (Scientific Reports, (2023), 13, 1, (17235), 10.1038/s41598-023-43287-4)
Scientific Reports
-
Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Gut, Vol. 72, Núm. 11, pp. 2031-2037
-
Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study
Cancers, Vol. 15, Núm. 3
-
Comparison of the management of Helicobacter pylori infection between the older and younger European populations
Scientific Reports, Vol. 13, Núm. 1
-
Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)
Gut, Vol. 72, Núm. 6, pp. 1054-1072
-
Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management
Journal of Clinical Medicine, Vol. 12, Núm. 13
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
2022
-
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)
Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2243-2257
-
Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: A Spanish Multicentre Study
Journal of Clinical Medicine, Vol. 11, Núm. 17
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry
Digestive and Liver Disease, Vol. 54, Núm. 5, pp. 635-641
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24